AMG 102

DRUG4 trials

Sponsors

Amgen, NantCell, Inc., Katy Peters

Conditions

CancerCastrate-Resistant Prostate CancerEsophageal CancerEsophagogastric Junction AdenocarcinomaExtensive-stage Small Cell Lung CancerGastric CancerGlioblastoma MultiformeGliosarcoma

Phase 1

AMG 102 Plus ECX for Unresectable Locally Advanced or Metastatic Gastric or Esophagogastric Junction Cancer

CompletedNCT00719550

AmgenEsophageal Cancer, Esophagogastric Junction Adenocarcinoma, Gastric Cancer

Start: 2009-02-28End: 2013-06-30Updated: 2013-12-05

AMG 102 in Combination With Mitoxantrone and Prednisone in Subjects With Previously Treated Castrate Resistant Prostate Cancer

CompletedNCT00770848

AmgenCancer, Castrate-Resistant Prostate Cancer, Mestastatic Prostate Cancer +1

Start: 2008-11-30End: 2012-04-30Updated: 2014-03-10

QUILT-2.013: First-Line Treatment for Extensive Stage Small Cell Lung Cancer

TerminatedNCT00791154

NantCell, Inc.Extensive-stage Small Cell Lung Cancer, Lung Cancer, Small Cell Lung Cancer +1

Start: 2008-12-02End: 2013-05-01Updated: 2024-08-23

Phase 2

AMG 102 and Avastin for Recurrent Malignant Glioma

CompletedNCT01113398

Katy PetersGlioblastoma Multiforme, Gliosarcoma

Start: 2010-08-31End: 2015-09-30Updated: 2015-12-10

Related Papers

DI-033 Clinical response of rilotumumab in solid tumours

2016-02-14

Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study.

2014-06-22203 citations